- Trial phase
- Phase 3
- Time to market
- Unknown, DAYBREAK Phase 3 readout is positive, but Tabirafusp (KSI-501) still requires regulatory review and a separate Phase 3 ALTO study in DME. If prioritized, potential approval could be 2-3+ years out.
- Why 4/10
- The pivotal DAYBREAK Phase 3 readout for Tabirafusp alfa tedromer (KSI-501) in wet AMD already occurred on September 28, 2026, the binary event has passed. The next hard dated catalyst for this specific drug is not yet dated, the ALTO Phase 3 study of KSI-501 in DME is ongoing but has no announced topline readout date. With the primary binary catalyst behind it, impactScore is 4 per the rubric (post-pivotal-readout stage.
The DAYBREAK Phase 3 readout (Sept 28, 2026) was the defining binary catalyst for Tabirafusp, it was a clear success, driving the stock from ~$32 to ~$90. The next catalysts are the PEAK Phase 3 readout for KSI-101 (Dec 2026) and the Zenkuda BLA submission (Q4 2026), but these are separate pipeline assets. For Tabirafusp specifically, watch for the ALTO Phase 3 study in DME and any regulatory path updates. The stock now trades near analyst targets ($103-$145 range) with ~39% implied upside to the mean target of $122.
Price Chart
Executive Summary
Tabirafusp alfa tedromer (KSI-501) is Kodiak Sciences' bispecific antibody for wet age-related macular degeneration, tested in the pivotal DAYBREAK Phase 3 study (NCT06556368) alongside tarcocimab tedromer (Zenkuda) vs aflibercept. The DAYBREAK topline results were announced September 28, 2026, a resounding success, the stock surged from ~$32 to ~$90 in a single day (opening $61.70, high $95.77, close $89.92 on 38.5M shares). The stock now trades at $87.63 with strong analyst support (9/9 Buy/Strong Buy, mean target $121.67, implied 39% upside. However, the binary catalyst has already been priced in, the company remains pre-revenue with $125.9M cash burning ~$42M/quarter, and a $350M ATM overhang from the October 2026 S-3ASAR filing creates dilution risk. The next catalysts are the PEAK Phase 3 readout (KSI-101 in MESI, December 2026) and Zenkuda BLA submission (Q4 2026).
How It Works
Tabirafusp alfa tedromer (KSI-1351) is a bispecific antibody designed to treat wet age-related macular degeneration (wet AMD), a leading cause of blindness. It targets two disease pathways simultaneously, VEGF (a protein that drives abnormal blood vessel growth) and another inflammatory target, using Kodiak's ABC (Antibody Biopolymer Conjugate) platform designed to enable longer-lasting treatment effects, potentially allowing patients to receive injections less frequently than current standard-of-care drugs like Eylea and Vabysmo.
Trial Status
The DAYBREAK Phase 3 study (NCT06556368) in wet AMD is ACTIVE_NOT_RECRUITING with primary completion estimated August 2026 (actual completion estimated 2027-2026). Topline results were presented September 28, 2026 and were strongly positive, stock surged ~178% in a single day. The ALTO Phase 3 study of KSI-501 in diabetic macular edema (DME) is ongoing.
The Two-Sided Case
Upcoming Catalysts
- PEAK Phase 3 topline data for KSI-101 in MESI (December 2026)
- BLA submission for Zenkuda (tarcocimab tedromer) in Q4 2026
- ALTO Phase 3 study of KSI-501 in DME, topline readout (no date yet)
- Potential regulatory updates on Tabirafusp/KSI-501 path
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Kodiak Sciences Inc. S-3ASR KOD ·Originating report